Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
Eli Lilly (LLY) stock jumped following earnings which saw its diabetes drug Monjaro sales soar and news it could reduce heart risk.
Eli Lilly (LLY) shares have been soaring as Mounjaro for weight loss and Donanemab for Alzeimer’s could fuel profits for years.
Eli Lilly (LLY) capped the price of insulin it provides to Americans at $35 a month. But LLY’s weight loss drug should be the big news.
Eli Lilly (LLY) continues to rise as it has developed what could become the next big weight loss drug, pending approval from the FDA.
Eli Lilly (LLY) has two potential blockbuster drugs — for weight loss and Alzheimer’s — that could bring big profits down the road.
Eli Lilly (LLY) is expected to report qtrly profits (EPS) and revenues:
Profits Estimates: $2.51 vs. $1.62 = +55%
Revenue Est: +29%
